文献速递消化道肿瘤与早癌

磷酸二酯酶5抑制剂使用与良性结直肠肿瘤男性结直肠癌风险降低相关

Use of Phosphodiesterase 5 Inhibitors Is Associated With Lower Risk of Colorectal Cancer in Men With Benign Colorectal Neoplasms.
PubMed 文献 · Gastroenterology · 2019-05-16

瑞典全国性队列研究纳入2005年7月至2015年3月诊断为良性结直肠肿瘤的男性,分析PDE5抑制剂使用与结直肠癌风险的关系。PDE5抑制剂处方者结直肠癌发病率为2.64/1000人年,未处方者为4.46/1000人年;校正后HR为0.65(95%CI 0.49-0.85)。结论认为PDE5抑制剂使用与结直肠癌风险降低相关,需进一步研究确认。

要点

  • 良性结直肠肿瘤男性中,PDE5抑制剂使用与结直肠癌风险降低相关(校正HR 0.65,95%CI 0.49-0.85)。
  • 结直肠癌风险降低与PDE5抑制剂累积剂量增加相关(P = .003)。
  • PDE5抑制剂处方与晚期结直肠癌风险降低的关联(校正HR 0.61)与早期(校正HR 0.70)差异无统计学显著性。

核心结论

  • 在瑞典良性结直肠肿瘤男性全国性人群研究中,PDE5抑制剂使用与结直肠癌风险降低相关,需进一步研究确认该关联。

研究设计与样本

  • 全国性基于人群的队列研究,纳入2005年7月至2015年3月瑞典医院出院登记中诊断为良性结直肠肿瘤的男性。
  • 通过链接瑞典其他国家登记获取PDE5抑制剂处方和结直肠癌诊断信息,采用Cox回归计算HR和95%CI。

主要发现

  • 研究期间共4823例患者被处方PDE5抑制剂;PDE5抑制剂处方者结直肠癌发病率为2.64/1000人年,未处方者为4.46/1000人年。
  • PDE5抑制剂使用与结直肠癌风险呈显著负相关(校正HR 0.65,95%CI 0.49-0.85)。
  • 结直肠癌风险降低与PDE5抑制剂累积剂量增加相关(P = .003)。
  • PDE5抑制剂处方与晚期结直肠癌风险降低的关联(校正HR 0.61,95%CI 0.37-1.00)大于早期结直肠癌(校正HR 0.70,95%CI 0.50-0.98),但差异无统计学显著性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究确认观察到的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Phosphodiesterase 5 (PDE5) inhibitors have been proposed to have chemopreventative effects on colorectal cancer (CRC), although data are needed from population-based studies. We performed a nationwide cohort study to investigate the association between the use of PDE5 inhibitors and the risk of CRC in men with benign colorectal neoplasms. METHODS: We identified men who received a diagnosis of benign colorectal neoplasm from July 2005 through March 2015 who were listed in the Swedish Hospital Discharge Register. We linked data with those from other national Swedish registers to obtain information about the prescription of PDE5 inhibitors and CRC diagnoses. Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: A total of 4823 patients were prescribed PDE5 inhibitors during the study period; the incidence rate of CRC was 2.64 per 1000 person-years for men prescribed PDE5 inhibitors compared with 4.46 per 1000 person-years for men without a prescription. We found a significant negative association between PDE5 inhibitor use and risk of CRC (adjusted HR, 0.65; 95% CI, 0.49-0.85); the decreased risk of CRC was associated with an increased cumulative dose of PDE5 inhibitors (P = .003). PDE5 prescription was associated with greater reduction in risk of advanced-stage CRC (adjusted HR, 0.61; 95% CI, 0.37-1.00) than early-stage CRC (adjusted HR, 0.70; 95% CI, 0.50-0.98), but the difference was not significant. CONCLUSIONS: In a nationwide population-based study of men with a diagnosis of benign colorectal neoplasm in Sweden, we found evidence that use of PDE5 inhibitors is associated with a reduced risk of CRC. Further studies are needed to confirm the observed association.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Huang W, Sundquist J, Sundquist K, et al. Use of Phosphodiesterase 5 Inhibitors Is Associated With Lower Risk of Colorectal Cancer in Men With Benign Colorectal Neoplasms. Gastroenterology. 2019. PMID: 31103628. doi:10.1053/j.gastro.2019.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。